GlassScriptPhysician profile
Daniel R Whipple
NPI 1164413431
$3,318.36
in general payments reported to CMS, 2019-2025
27 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $263 · 2021: $364 · 2022: $704 · 2023: $450 · 2024: $728 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,127.61 | 2019-2025 | Clareon, Rocklatan, Centurion |
| Bausch & Lomb Americas INC. | $458.80 | 2022-2025 | Ic-8 Apthera Iol, Stellaris, Xiidra |
| Regeneron Healthcare Solutions, INC. | $358.19 | 2019-2025 | Eylea Hd, Eylea |
| Tarsus Pharmaceuticals, INC. | $141.93 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $118.38 | 2020-2021 | |
| Genentech USA, INC. | $111.93 | 2023-2025 | Vabysmo |
| Allergan, INC. | $110.05 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $103.15 | 2019-2022 | |
| Horizon Therapeutics Plc | $98.40 | 2019-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $87.46 | 2019-2020 | |
| Abbvie INC. | $73.78 | 2023-2025 | Alphagan P, Lumigan, Durysta |
| Thea Pharma INC. | $65.27 | 2022-2024 | Iyuzeh |
| Carl Zeiss Meditec, INC. | $59.06 | 2022-2024 | |
| Harrow Eye, LLC | $44.99 | 2024 | Triesence, Iheezo |
| Alimera Sciences, INC. | $43.74 | 2024 | Iluvien, Yutiq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $40.47 | 2021-2024 | |
| Astellas Pharma US INC | $36.03 | 2023-2025 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $35.45 | 2024-2025 | Baerveldt Glaucoma Implant (250), Tecnis Simplicity |
| Cumberland Pharmaceuticals, INC. | $31.97 | 2021 | |
| Rxsight INC | $27.27 | 2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Apellis Pharmaceuticals, INC. | $25.97 | 2022 | |
| Tearlab Corp | $24.73 | 2019 | |
| Dompe US, INC. | $24.53 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $21.14 | 2019 | |
| New World Medical,INC. | $18.07 | 2022 | |
| Sight Sciences, INC. | $15.93 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Glaukos Corporation | $14.06 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Whipple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.